This vignette demonstrates a synthetic benchmark workflow for
pharmax.ml. It is exploratory decision support only. It
does not establish clinical validity or regulatory validation.
known_signal <- px_simulate_covariates(n = 120, scenario = "known_signal", seed = 2026)
missingness <- px_simulate_covariates(n = 120, scenario = "missingness", seed = 2026)
head(known_signal)
#> COV_WT COV_AGE COV_ALB COV_SCR COV_BMI ETA_CL ETA_V
#> 1 75.20589 77.87445 4.305298 1.1913715 29.56883 0.7490751 0.5630393
#> 2 59.20309 80.58157 4.244168 0.5323115 31.62620 -0.7731816 -0.2646415
#> 3 71.39238 57.77748 4.678305 0.5336162 26.30571 0.1801818 1.0679644
#> 4 69.15251 65.76335 4.493324 0.6517231 23.14172 0.1674935 0.5781191
#> 5 63.33360 34.13449 4.198195 1.1766099 34.41520 -0.5519423 0.3772962
#> 6 44.83911 60.62618 4.191514 1.1256459 33.73746 -1.8423279 -0.7352037
sum(is.na(missingness))
#> [1] 25benchmark <- px_benchmark_covariate(
scenarios = c("known_signal", "no_signal", "correlated", "missingness"),
replicates = 3,
n = 100,
method = "cor",
seed = 2026
)
benchmark
#> pharmax covariate benchmark
#>
#> # A tibble: 4 × 5
#> scenario replicates signal_top_rate median_signal_rank mean_top_importance
#> <chr> <int> <dbl> <int> <dbl>
#> 1 correlated 3 1 1 0.460
#> 2 known_signal 3 1 1 0.714
#> 3 missingness 3 1 1 0.730
#> 4 no_signal 3 0.333 5 0.443
#>
#> Interpretation: synthetic evidence for screening behavior, not clinical validation.quality <- px_data_quality(known_signal, impute = "median")
screen <- px_covariate(quality$data, method = "auto", n_top = 3, seed = 2026)
calibration <- px_calibrate_conformal(
truth = known_signal$ETA_CL[1:40],
lower = known_signal$ETA_CL[1:40] - 0.5,
upper = known_signal$ETA_CL[1:40] + 0.5,
prediction = known_signal$ETA_CL[1:40],
alpha = 0.1
)
px_ml_report(
screen,
quality = quality,
calibration = calibration,
benchmark = benchmark,
context = list(context_of_use = "Synthetic covariate-screening demonstration")
)
#> pharmax ML decision-support report
#>
#> Top signals:
#> # A tibble: 2 × 6
#> parameter covariate importance methods method_agreement rank
#> <chr> <chr> <dbl> <chr> <int> <int>
#> 1 ETA_CL COV_WT 0.839 aalasso, cor, elastic_n… 5 1
#> 2 ETA_V COV_ALB 0.954 aalasso, cor, elastic_n… 5 1
#>
#> Limitations:
#> * Exploratory decision support only.
#> * Synthetic/public examples do not establish clinical validity.
#> * Human pharmacometric review is required before acting on results.
#>
#>
#> Human oversight: Outputs are intended for human-reviewed model-informed workflow support.